UCB’s bimekizumab, after FDA rejection in psoriasis, proves its worth in hidradenitis suppurativa zbecker Fri, 12/09/2022 – 16:28 More: UCB's bimekizumab, after FDA rejection in psoriasis, proves its worth in hidradenitis suppurativa Source: fierce
read moreCombo of Roche’s Tecentriq and Exelixis’ Cabometyx fails another trial, this time in lung cancer fkansteiner Fri, 12/09/2022 – 11:22 More: Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer Source: fierce
read moreFierce Pharma Asia—MEI and Kyowa Kirin’s PI3K woes; Takeda’s dengue nod, Daiichii Sankyo’s Enhertu positivity esagonowsky Fri, 12/09/2022 – 10:43 More: Fierce Pharma Asia—MEI and Kyowa Kirin’s PI3K woes; Takeda’s dengue nod, Daiichii Sankyo’s Enhertu positivity Source: fierce
read moreSenator presses Amgen with ‘final request’ for information in tax probe kdunleavy Fri, 12/09/2022 – 09:50 More: Senator presses Amgen with 'final request' for information in tax probe Source: fierce
read moreAZ writes the ‘next chapter’ in Enhertu’s saga with head-to-head win versus Roche’s Kadcyla fkansteiner Fri, 12/09/2022 – 09:22 More: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla Source: fierce
read moreFacility represents one of the largest commercial-scale operations in the world More: Catalent completes cell therapy manufacturing facilities in Belgium Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals